Premium
Carbamazepine‐induced thrombocytopenia defined by a challenge test
Author(s) -
Ishikita Takashi,
Ishiguro Akira,
Fujisawa Kohji,
Tsukimoto Ichiro,
Shimbo Toshikazu
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199909)62:1<52::aid-ajh9>3.0.co;2-e
Subject(s) - carbamazepine , medicine , platelet , rash , prednisolone , anticonvulsant , epilepsy , gastroenterology , pharmacology , immunology , psychiatry
Carbamazepine (CBZ), a widely used anticonvulsant, occasionally causes serious hematologic disorders. A 12‐year‐old boy was admitted because of a diffuse petechial rash and profound thrombocytopenia (10 × 10 9 platelets/l), after having been treated for epilepsy with CBZ for 12 days. Seven days following withdrawal of CBZ and initiation of prednisolone therapy, the platelet count recovered. In a subsequent challenge test with CBZ, platelet counts again decreased, and the levels of platelet‐associated IgG and serum interleukin‐6 increased. No antibodies against platelet glycoprotein IIb/IIIa or Ib were detected in plasma. We believe that this is the first reported occasion when CBZ‐induced thrombocytopenia has been defined by a rechallenge test. Am. J. Hematol. 64:52–55, 1999. © 1999 Wiley‐Liss, Inc.